You will need to be careful to avoid interactions with other drugs, particularly those that treat various digestive issues
Semaglutide GLP-1 S, on the other hand, is studied within a much broader and more validated use case, with trial data reporting average body weight reductions exceeding 14% over 68 weeks a proof point that has made GLP-1 receptor agonists a far more established research category for metabolic and weight-related studies than growth hormone fragment peptides like AOD-9604
On the other hand, laboratory studies in animals indicate that BPC-157 is well-tolerated with minimal toxicity, even at elevated doses [25]
People who eat quickly, have had general anesthesia, have trouble swallowing or coughing, are 65 and older, have a weakened immune system, use feeding tubes, have had a stroke, drink large amounts of alcohol and are unable to chew properly are the most at risk for aspiration and aspiration pneumonia
b) support in least restrictive environments c) eligibility for support services